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Abstract
Background: Turkey reproduction is by artificial insemination using pooled semen so there is
interest in storing semen. Fertilizing capacity declines after six hours storage, possibly due to poor
sperm mobility. Prostaglandins (PG) affect mammalian sperm motility, but avian sperm has not been
widely studied. For this study, levels of PG E1, E2, and F2 alpha in turkey seminal plasma and sperm
extract, and effects of cyclooxygenase (COX) inhibitors on sperm mobility were determined.
Methods: Seminal Plasma and sperm extract PG E1, E2, and F2 alpha, from 1.0 mL pooled semen,
were measured by ELISA. In Trial 1, PG were determined from 122 wk old toms (n = 4). Trial 2
used 36 wk old toms (n = 7). For Trial 3, PGE2 only was measured from 48 wk (n = 6) and 154 wk
old toms (n = 3). The effects of non-specific COX inhibitors indomethacin, diclofenac, tolmetin, or
aspirin (n = 10), or specific COX-1 or COX-2 inhibitors (n = 3) on sperm mobility were measured
(Accudenz swim-down test).
Results: Seminal plasma PG (pg/mL) in Trials 1 and 2, respectively, were 185.2 ± 88.4 and 187.2 ±
33.7 for PGE1; 141.4 ± 43.1 and 100.4 ± 14.6 for PGF2 alpha; and 431.0 ± 155.1 for PGE2 (Trial 1
only). Sperm extract PG (pg/10 billion cells) in Trials 1 and 2, respectively, were 215.1 ± 38.1 and
208.9 ± 41.5 for PGE1; 133.7 ± 51.7 and 49.8 ± 8.3 for PGF2 alpha; and 52.3 ± 8.6 for PGE2 (Trial
1 only). In Trial 3, seminal plasma PGE2 (pg/mL) in older versus younger males was 1097.9 ± 99.3
versus 853.2 ± 144.6 and sperm extract PGE2 (pg/10 billion cells) was 208.0 ± 56.1 versus 102.4 ±
14.8. Cyclooxygenase inhibitors (0.001 to 10 mM) decreased sperm mobility: indomethacin 15 to
100%; diclofenac 4 to 100%; tolmetin 27 to 74%; aspirin (tested at 0.01 to 15 mM) 22 to 42%;
resveratrol (COX-1) and NS-398 (COX-2), both tested at 0.1 to 10 mM, 38 to 98% and 44 to 85%,
respectively.
Conclusion: These results indicate that PG are present in turkey seminal plasma and sperm, and
COX inhibitors decrease turkey sperm mobility.
Background
Commercial breeders use artificial insemination (AI) for
reproduction of domestic turkeys (Meleagris gallopavo).
Semen is collected from a flock of toms, pooled, and
diluted prior to insemination of hens. A goal for breeders
has been extending the interval between semen collection
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and time of insemination. Cryopreservation has not given
satisfactory results, for even when suitable extenders and
adequate oxygen is supplied, turkey semen cannot be
stored for more than six hours without a loss in fertilizing
capacity [1–5]. Fertilizing capacity has been correlated
with sperm mobility of individual chicken and turkey
males [6–12] as well as pooled turkey semen [13] using
the Sperm Mobility Test (SMT). The SMT measures the
ability of sperm to penetrate an Accudenz® solution. The
assay allows objective measurement of the proportion of
sperm that move with forward linear movement, i.e.,
mobility. Researchers attempting to develop successful
storage regimens for turkey semen base their investiga-
tions on the rationale that by preserving sperm mobility,
the fertilizing capacity of the stored semen can be
improved.
Prostaglandins are eicosanoid hormones that have been
shown to have varied effects on mammalian sperm motil-
ity. Schlegel et al. [14] found that PGF2a was negatively
correlated with human sperm motility, but disruption of
prostaglandins with 15-hydroxydehydrogenase also
caused a dramatic decrease in motility. High levels of
PGF2α were also found to suppress bull sperm motility
and induce membrane damage [15]. Studies of human
sperm have shown that prostaglandins of the E series pro-
mote calcium influx via a receptor-linked mechanism that
is capable of inducing the acrosome reaction [16,17]. In
general, prostaglandins of the E series stimulate sperm
motility, whereas PGF2α inhibits motility [18,19]. Little is
known on the effects of PG on avian sperm.
The formation of the most common seminal prostaglan-
din series, the series-2 prostaglandins, involves conver-
sion of arachidonic acid to cyclic endoperoxides by
cyclooxygenase (COX), followed by conversion of the
endoperoxides to prostaglandin by prostaglandin isomer-
ase [20]. Multiple forms of the COX enzyme exist, distin-
guished by expression patterns in mammalian tissues. The
COX-1 enzyme is constitutively expressed and regulates
normal physiological processes such as gastrointestinal,
renal, and platelet function. In contrast, COX-2 is induci-
ble by such factors as hormones, growth factors, and
cytokines and functions to generate prostaglandins
involved in the inflammatory process [21]. A variant of
the COX-1 enzyme, COX-3, has been found in canine cer-
ebral cortex and human cerebral cortex and heart [22].
While the anti-inflammatory and analgesic effects of non-
steroidal anti-inflammatory drugs are generally thought
to be due to inhibition of COX, recent evidence suggests
that these types of compounds may have additional activ-
ities independent of COX inhibition [23].
The purpose of this study was to determine the levels of
PG E1, E2, and F2α in turkey seminal plasma and sperm
extract, and the effects of cyclooxygenase (COX) inhibi-
tors on sperm mobility.
Methods
Experimental Animals
Small White Turkey toms bred for high egg production
[24] were used in these studies. Approval for the use of
animals was obtained from the Animal Research Commit-
tee at Clemson University. The turkeys were maintained in
closed houses with free access to feed and water. Two
flocks of turkeys were used and were classified as Group 1
(older toms) and Group 2 (younger toms). Group 1 was
106 wk older than Group 2. Beginning at 29 wk old, both
flocks of toms were placed on the following light regimen
to initiate semen production: fluorescent light (Cool
White Delux, Sylvania F40CWX, GTE Products Corp., Ver-
sailles, KY) at 189 lx intensity at head height with a 14
hour light/10 hour dark cycle. All toms received a 2,650
kcal ME/kg diet containing 12% protein. Semen was col-
lected by abdominal massage [25].
Determination of Sperm Concentration
Sperm concentration was determined using a modifica-
tion of the technique of Donoghue et al. [26]. A 10 µL
aliquot of semen or semen dilution was added to 2 mL of
3% sodium chloride in a 4.0 mL polystyrene cuvette. The
cuvette was inverted 10 times to mix, and the absorbance
was read at 550 nm using a Turner SP-830 spectropho-
tometer (Thermolyne Corp., Dubuque, IA). Sperm con-
centration was then determined using a standard curve
prepared from diluted semen samples of known concen-
tration as determined by counting in a sperm/bacteria
counting chamber (Petroff-Hausser Counter, Hausser Sci-
entific, Horsham, PA).
Prostaglandin Concentrations in Turkey Spermatozoa and 
Seminal Plasma
Semen Collection
Samples of pooled semen were collected from Small
White turkey toms at three separate times for PG measure-
ment. Semen PGE1, PGE2, and PGF2a were measured for
Group 1 males when they were 122 wk old (Trial 1, n = 4)
and for Group 2 males at 32 wk of age (Trial 2, n = 7). An
error occurred for the standard curve for PGE2 in Trial 2,
so a third trial was done in which semen was collected
from both Group 1 (154 wk old, n = 3) and Group 2 birds
(48 wk old, n = 6) to repeat the measurement of PGE2.
For each trial, toms were randomly selected for semen col-
lection from the group or groups being tested, and the
semen was alternately added to successive 1.5 mL micro-
centrifuge tubes to produce the number of pools of semen
indicated above. This was repeated until all tubes had 1.0
mL of semen pooled from three or four birds, and eachReproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/74
Page 3 of 7
(page number not for citation purposes)
microcentrifuge tube of pooled semen was considered an
independent sample.
Seminal Plasma Preparation
After collection, each pooled sample was centrifuged at
12000 × g for 2 min in a microcentrifuge (Biofuge 13, Her-
aeus Instruments, Inc., South Plainfield, NJ). The seminal
plasma was removed from the sperm pellet, transferred to
a new 1.5 mL microcentrifuge tube, and centrifuged at
12000 × g twice for 2 min each. Following the final cen-
trifugation, the seminal plasma was filtered using a 0.2
µm syringe filter and diluted 1/10 with Assay Buffer ED1.
Spermatozoal Extracts
The sperm pellet remaining after removal of seminal
plasma was washed by centrifugation two times with tris-
buffered saline (TBS, 0.02 M tris/0.5 M sodium chloride,
pH 7.5). The pellet was then resuspended to 1.5 mL in TBS
and sperm concentration was determined as described
above. An aliquot of the sperm suspension containing 5 ×
109 sperm was placed in a microcentrifuge tube (1.5 mL)
and centrifuged. The supernatant was discarded, 0.5 mL of
TBS was added to the pellet, and the pellet was homoge-
nized using a Pellet Pestle (Kontes Glass Company, Vine-
land, NJ). The homogenized pellet was sonicated (Vibro
Cell, Sonics and Materials Inc., Danbury, CT) at 50%
power with an alternating 15 sec. on, 15 sec. off regimen
that was repeated sequentially four times. The sample was
centrifuged, the sperm extract (supernatant) was col-
lected, and the volume determined. The sperm extract was
then diluted 1/10 with Assay Buffer ED1.
Enzyme-linked Immunosorbent Assay (ELISA)
Concentrations of PGE1, PGE2, and PGF2α were deter-
mined using competitive binding ELISA kits (R & D Sys-
tems, Minneapolis, MN) which contained antibodies,
standards, and reagents. Cross-reactivities of the antibod-
ies that were greater than 5% were as follows: the PGE1
antibody had 6.5% and 2.2% cross-reactivity with PGE2
and PGE3, respectively; the PGE2 antibody had 70% and
16.3% cross-reactivity with PGE1 and PGE3, respectively;
and the PGF2α antibody had 11.8% or 20% cross-reactiv-
ity with PGF1α depending upon the kit used. Three repli-
cate wells were used per sample, and the samples from
each trial were assayed separately at the time of collection.
The absorbance at 405 nm was inversely proportional to
PG concentration, which was determined from a standard
curve of absorbance versus prostaglandin concentration
generated using a four-parameter logistic curve fit with
Softmax software (Molecular Devices Corp., Menlo Park,
CA).
Effect of Cyclooxygenase (COX) Inhibitors on Sperm 
Mobility
Semen Collection/Sperm Concentration
Semen from turkey toms (68 wk old at the beginning of
these studies) was used to test the effect of six COX inhib-
itors on sperm mobility. One inhibitor was tested per
week, and all assays for that inhibitor were completed
before proceeding to the next inhibitor. Semen was
pooled in a 1.5 mL microcentrifuge tube until approxi-
mately 1.0 mL was obtained (sample 1). The sperm con-
centration was determined as described above, and the
semen was diluted to 1.0 × 1010 sperm/mL with Mobility
Buffer (MB) consisting of 50 mM N-tris(hydroxyme-
thyl)methyl-2-aminoethanesulfonic acid/128 mM
sodium chloride/2 mM calcium chloride, pH 7.4, 280 to
320 mOsm/kg. The sperm mobility, with and without
COX inhibitor, was determined for the sample as
described below. Then another semen sample was col-
lected, and the procedure was repeated until a total of ten
samples had been assayed for each inhibitor, except for
the specific COX-1 and COX-2 inhibitors where three
samples were assayed.
COX Inhibitor Treatments
Inhibitors used were indomethacin, diclofenac sodium,
tolmetin, acetylsalicylic acid, resveratrol, and NS-398
(I7378, D6899, A5376, T6779, R5010, and N-194, Sigma
Chemical Company, St. Louis, MO). Resveratrol and NS-
398 are specific inhibitors of the COX-1 and COX-2
enzymes, respectively. A volume of 100 µL of semen that
had been diluted to 1.0 × 1010 sperm/mL was added to
900 µL of MB with or without inhibitors such that the
final concentrations of inhibitor was 0 to15 mM. Due to
the limited solubility of diclofenac, indomethacin, resver-
atrol, and NS-398, these COX inhibitors were first dis-
solved in dimethyl sulfoxide (DMSO) and then added to
MB such that the final concentration of DMSO was 5%.
For all treatments, mobility was determined using the
Sperm Mobility Test (SMT) as described below. Aliquots
of semen diluted with the various treatments were also
examined microscopically (CH-2, Olympus Corporation,
Lake Success, NY) to assess sperm morphology.
Sperm Mobility Test (SMT)
Sperm mobility was determined using a procedure devel-
oped for chicken semen [6] and modified for turkey
semen [9]. For each assay, a volume of 0.06 mL of semen
diluted as described above was overlayered onto 0.6 mL of
prewarmed (41°C) 4% Accudenz® (Accurate Chemical
and Scientific Corp., Dubuque, IA) solution in a 1.5 mL
polystyrene cuvette. The cuvette was incubated at 41°C
for 5 minutes in a dry bath (Thermolyne Corp., Dubuque,
IA). Following incubation, the cuvette was placed in the
Turner SP-830 spectrophotometer. After 1 minute, theReproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/74
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absorbance was recorded at a wavelength of 550 nm.
Accudenz® solution (4%, 41°C) was used as the blank.
Statistical Analysis
Prostaglandin Concentrations
The means and SEM of the PG concentrations in turkey
seminal plasma and sperm extract were generated using
the Descriptive Statistics package in Microsoft Excel 2000
(Microsoft Corp., Redmond, WA). In Trial 3, PGE2 levels
in seminal plasma and sperm extracts of younger versus
older toms were analyzed using a Student's t-test.
Sperm Mobility Scores
For each COX inhibitor tested, the absorbance values
from sample aliquots that contained no drug (Control)
were equated to 100% mobility. The absorbance values
from sample aliquots containing COX inhibitors were
expressed as the percentage of the value from the respec-
tive Control sample aliquot. The percentage data were arc-
sine transformed and analyzed using the General Linear
Model procedure and Duncan's Multiple Range test of SAS
(SAS Institute Inc., Cary, NC). Significance was deter-
mined at P ≤ 0.05.
Results
Prostaglandin Concentrations in Turkey Seminal Plasma 
and Sperm Cells
Seminal Plasma
The PG concentrations found in seminal plasma of turkey
toms are shown in Table 1 (Trial 1 and 2). Results for
PGE2 concentrations in Trial 2 were discarded due to an
error in the standard curve. In Trial 3, PGE2 concentrations
(pg/mL) in seminal plasma were not different (P ≤ 0.05)
between older (1097.9 ± 99.0) and younger (853.2 ±
144.6) males.
Sperm Extract
The prostaglandin concentrations found in extracts of tur-
key sperm are shown in Table 2 (Trial 1 and 2). Results for
PGE2 concentrations in Trial 2 were discarded due to an
error in the standard curve. In Trial 3, the PGE2 concentra-
tion (pg/109 cells) in sperm extracts from older birds
(208.0 ± 56.1) was significantly higher when compared to
that from younger birds (102.4 ± 14.8).
Effect of Cyclooxygenase Inhibitors on Sperm Mobility
DMSO Test
As DMSO was required to solubilize some of the COX
inhibitors, a preliminary experiment testing the effects of
5% DMSO on sperm was performed. No significant differ-
ence was seen in sperm mobility when 5% DMSO was
added to the assay (OD = 0.355 ± 0.016) when compared
to results using MB alone (OD = 0.353 ± 0.020).
COX Inhibitor Treatments
The effects of general COX inhibitors on sperm mobility
are shown in Table 3. Values have been expressed as a per-
centage of the Control, which contained no drug and was
equated to 100% mobility. All compounds tested caused
a progressive decline in sperm mobility with increasing
dosage: indomethacin (0.001 to 10 mM) 15 to 100%;
diclofenac (0.001 to 10 mM) 4 to 100%; tolmetin (0.001
to 10 mM) 27 to 74%, and aspirin (0.01 to 15 mM) 22 to
42% inhibition. Indomethacin significantly depressed
sperm mobility above concentrations of 0.1 mM. The
results with diclofenac sodium were similar to those seen
with indomethacin. Tolmetin also inhibited mobility, but
inhibition was only 20 to 25% until the concentration
exceeded 1.0 mM. Aspirin resulted in only 15 to 23% inhi-
bition even at concentrations as high as 10 mM.
The effects of specific inhibitors of COX-1 and COX-2 on
sperm mobility are shown in Table 4. Addition of 0.1 mM
to 10 mM resveratrol (COX-1) or NS-398 (COX-2)
resulted in 38 to 98% inhibition for resveratrol and 44 to
85% inhibition for NS-398. Similar to indomethacin and
diclofenac, both resveratrol and NS-398 depressed sperm
mobility approximately 38% at the 0.1 mM level and 80%
or greater at the 1 mM level.
When semen samples diluted in MB containing COX
inhibitors were examined microscopically, sperm were
generally intact. However, at the 10 mM level of
indomethacin and diclofenac, mostly debris was seen
with only a few intact, immobile sperm.
Discussion
For mammals, seminal PG are produced mainly in the
accessory glands of the reproductive tract, and PG have
been shown in vitro to affect sperm motility, capacitation,
and the acrosome reaction [16–18,27–29]. In contrast,
Table 1: Prostaglandin concentrations (pg/mL) in seminal 
plasma1
Trial Number PGE1 PGE2 PGF2α
Trial 1A 185.2 ± 88.4 431.1 ± 155.1 141.4 ± 43.1
Trial 2B 187.2 ± 33.7 No Data 100.4 ± 14.6
1Mean ± SEM. A For Trial 1, n = 4. Group 1 toms: 122 wk old. B For 
Trial 2, n = 7. Group 2 toms: 36 wk old.
Table 2: Prostaglandin concentrations (pg/109 cells) in turkey 
sperm extract1
Trial Number PGE1 PGE2 PGF2α
Trial 1A 215.1 ± 38.1 52.3 ± 8.6 133.7 ± 51.7
Trial 2B 208.9 ± 41.5 No Data 49.8 ± 8.3
1Mean ± SEM. A For Trial 1, n = 4. Group1 toms: 122 wk old. B For 
Trial 2, n = 7. Group 2 toms: 36 wk oldReproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/74
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avian species do not have accessory glands, nor do avian
spermatozoa undergo capacitation or a mammalian-like
acrosome reaction. Given these facts, it is perhaps not sur-
prising that reported PG levels in the seminal plasma of
aves [30,31], and those presented here, are lower than
those of most mammals, and that a role for avian seminal
PG is unknown. A probable mechanism whereby PG
could regulate sperm mobility would be through control
of calcium, an ion previously shown to be necessary for
turkey sperm mobility [32]. In this regard, PGE1 and PGE2
have been shown to promote calcium influx in mamma-
lian sperm [17].
Using RIA, Hertelendy [30] reported PGE levels of 300
and 200 pg/mL in seminal plasma of chicken and turkey,
respectively, and levels of PGF less than 100 pg/mL in
chicken seminal plasma. In the present study, seminal
plasma levels of PGE1 and PGF2α determined using ELISA
were comparable to levels reported by Hertelendy [30] for
PGE and PGF. No PG levels have been previously reported
for turkey sperm extracts. While the PG concentrations
detected in each trial were not statistically compared, in
general the values for PGE1 were consistent between Trial
1 and Trial 2. The levels of PGE2 in Trial 3, however, were
two to four times greater than those seen in Trial 1 for
both seminal plasma and sperm extract. The reason for
this difference is unknown, but does not appear to be
related to the age of the turkeys as levels of PGE2 were
higher in both young (48 wk old) and old toms (154 wk
old) in Trial 3 than for the 122 wk old turkeys used in Trial
1. It is also unlikely that this difference was due to the
ELISA kits themselves, as the standard curves performed
for each PGE2 assay were comparable, and the same anti-
body was supplied in each kit. For PGF2α, values in Trial 1
were somewhat higher than those found for Trial 2 for
both seminal plasma and sperm extract. These differences
may have been due to a change in the antibody used in the
PGF2α assay kit (with reported lower cross-reactivity), but
also may have been related to differences in age of the
birds (122 versus 36 wk for Group 1 versus Group 2,
respectively).
The accurate measurement of tissue PG concentrations is
not without pitfalls. Detected PG levels may not accu-
rately reflect the true endogenous tissue concentrations
because PG are easily degraded [33]. Furthermore, cross-
reactivity of the PG antibodies, especially the PGE2 anti-
body, contributes to variations in measuring specific PG
concentrations.
In Trial 3, the measured PGE2 in sperm of older toms ver-
sus that of younger toms was significantly elevated while
that in the seminal plasma was not. The reason for this is
unknown. While the difference was statistically signifi-
cant, the difference was not numerically great, and may
not be of physiological significance. The presence of PG in
these extracts, however, suggests that turkey sperm may
possess the enzyme systems necessary for PG synthesis.
Both human and bovine sperm have been reported capa-
ble of synthesizing PG from arachidonic acid precursor in
vitro [28,34], and it would be interesting to determine if
this ability is shared by turkey sperm.
The finding that COX inhibitors decreased turkey sperm
mobility may indicate that PG regulate mobility. Specific
Table 3: The effect of cyclooxygenase inhibitors on turkey sperm mobility1
Dose Level (mM) Indomethacin Diclofenac Sodium Tolmetin Aspirin
0.0 (Control)
0.001
100a 
84.9 ± 2.3b
100a 
97.6 ± 2.2b
100a
73.2 ± 4.2b
100a 
No Data
0.01 73.4 ± 3.2c 87.8 ± 1.9c 81.0 ± 4.3b 82.2 ± 3.5b
0.1 63.7 ± 1.2d 83.1 ± 2.1c 78.2 ± 6.1b 85.0 ± 4.4b
1.0 11.8 ± 0.8e 35.7 ± 3.0d 75.8 ± 4.7b 83.0 ± 3.8b
10.0 0.8 ± 0.2f 0.2 ± 0.2e 25.3 ± 1.9c 77.4 ± 3.8b
15.0 No Data No Data No Data 56.7 ± 3.4c
1Mean ± SEM. Values are expressed as the percentage of the Control which contained no drug (Control = 100%). a-f Within columns, values without 
common superscript differ significantly (P ≤ 0.05; n = 10).
Table 4: Inhibition of sperm mobility by specific COX-1 and COX-
2 inhibitors1
Dose Level (mM) Resveratrol (COX-1 
Inhibitor)
NS-398 (COX-2 
Inhibitor)
0.0 (Control) 100a 100a
0.1 61.7 ± 2.3b 55.7 ± 5.4b
1.0 20.0 ± 3.4c 2.1 ± 1.4d
10.0 2.2 ± 1.3d 15.0 ± 2.3c
1Mean ± SEM. Values are expressed as the percentage of the Control 
which contained no drug (Control = 100%). a-d Within columns, values 
without common superscript differ significantly (P ≤ 0.05; n = 3).Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/74
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inhibitors of both COX-1 and COX-2 produced the same
degree of inhibition, even at the concentration of 0.1 mM,
a level at which the COX-2 inhibitor was reported to have
no inhibitory effect on COX-1 activity [35]. However, in
vitro experiments involving the effects of drugs on cells
must be interpreted with caution. For example, in addi-
tion to inhibition of COX enzymes, diclofenac,
indomethacin and the specific COX-2 inhibitor SC-236
have been shown to uncouple mitochondrial respiration
and inhibit substrate oxidation and ATP turnover in rat
mitochondria and thymocytes [36]. Such activity in sperm
would likely decrease mobility. Direct toxicity also must
be considered. Rocha et al. [37] reported that indometh-
acin and NS-398 were toxic to renal medullary cell cul-
tures, but only at levels that greatly exceeded those
necessary for COX inhibition. Most interest concerning
the toxicity of PG inhibitors has focused on the gastroin-
testional tract, where it has been shown that they inhibit
colorectal carcinogenesis. The mechanism of this actions
is independent of COX-inhibition, possibly by decreasing
the cell-cycle regulating proteins p21 or inhibition of tran-
scription factors [23,38]. Such effects may not be relevant
for sperm, which do not divide.
In the present study, the 10 mM level of indomethacin
and diclofenac disrupted turkey sperm membranes, leav-
ing mostly debris with only a few recognizable spermato-
zoa. This effect might be due to mechanisms unrelated to
their action as COX inhibitors. However, sperm appeared
intact at lower doses of indomethacin and diclofenac, lev-
els at which there was still significant inhibition of mobil-
ity. Tribble et al [39] found that indomethacin causes
membrane damage by increasing permeability, along
with uncoupling oxidative phosphorylation. Turkey
sperm are sensitive to osmotic changes and increased per-
meability may have been a contributor in the membrane
damage observed for indomethacin and diclofenac in this
study. Disintegration of sperm was not seen with tolmetin
or aspirin at any of the dose levels tested, nor was it
observed when the specific COX-1 or COX-2 inhibitors
(resveratrol and NS-398) were tested.
Conclusions
These results indicate that PG are present in both seminal
plasma and spermatozoa of the domestic turkey, and
inhibition of COX may affect mechanisms of avian sperm
mobility, although effects of toxicity of the inhibitor or
actions via other mechanisms cannot be ruled out.
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